ENO1 and hepatocellular carcinoma: The upregulation of the glycolysis-related gene signature score is predominantly associated with poor prognosis in patients with HCC, suggesting that GGS may serve as a potential prognostic biomarker and therapeutic target for HCC, as exemplified by ENO1 functional validation.